Aminocaproic acid
- Generic Name
- Aminocaproic acid
- Brand Names
- Amicar
- Drug Type
- Small Molecule
- Chemical Formula
- C6H13NO2
- CAS Number
- 60-32-2
- Unique Ingredient Identifier
- U6F3787206
- Background
An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
- Indication
For use in the treatment of excessive postoperative bleeding.
- Associated Conditions
- Hemorrhage
- Associated Therapies
- -
Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 46
- Registration Number
- NCT04814433
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Activated Factor Seven in Traumatic Retro Peritoneal Hematoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- King Abdul Aziz Specialist Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04424563
- Locations
- 🇸🇦
King abd el Aziz specialist hospital, Ta'if, Saudi Arabia
A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 22
- Registration Number
- NCT02656472
- Locations
- 🇺🇸
Advocate Childrens Hospital, Oak Lawn, Illinois, United States
Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients
- Conditions
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Target Recruit Count
- 154
- Registration Number
- NCT02238288
- Locations
- 🇧🇷
Clementino Fraga Filho University Hospital, Rio de Janeiro, RJ, Brazil
PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)
- Conditions
- Interventions
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Emory University
- Target Recruit Count
- 29
- Registration Number
- NCT02074436
- Locations
- 🇺🇸
Atlanta VA Medical Center, Decatur, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
TXA vs. Amicar in Total Knee and Hip Arthroplasty
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Duke University
- Target Recruit Count
- 246
- Registration Number
- NCT02030821
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Epsilon Aminocaproic Acid Vs. Tranexamic Acid Vs. Placebo for Prevention of Blood Loss in Total Knee Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Heekin Orthopedic Research Institute
- Target Recruit Count
- 54
- Registration Number
- NCT01527968
Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Loma Linda University
- Target Recruit Count
- 100
- Registration Number
- NCT01248104
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 177
- Registration Number
- NCT00958581
- Locations
- 🇺🇸
New York University School of Medicine - Department of Orthopaedic Surgery - Spine, New York, New York, United States
Amicar Pharmacokinetics of Children Having Craniofacial Surgery
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Paul Stricker
- Target Recruit Count
- 18
- Registration Number
- NCT00912119
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.